Application 077363
- Type
- ANDA
- Sponsor
- RANBAXY
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | RIVASTIGMINE | RIVASTIGMINE TARTRATE | SOLUTION; ORAL | 2MG/ML | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Rivastigmine | RIVASTIGMINE | Zydus Lifesciences Limited | 966d59ea-5cea-4fef-8b96-e0efe885caf4 | 2025-11-17 | Rivastigmine | |
| Rivastigmine | RIVASTIGMINE | Northstar Rx LLC. | 8b809739-8381-4cc1-ab4a-5b17ab902a3d | 2025-11-14 | Warnings, Adverse reactions | Rivastigmine |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | American Health Packaging | 52781229-ee82-43f9-a113-4419a611978d | 2025-11-11 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | Major Pharmaceuticals | 39aadc39-0f4f-44f7-88de-83a0ea2ac332 | 2025-03-03 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| Rivastigmine | RIVASTIGMINE | Mylan Pharmaceuticals Inc. | 4ab335d1-19ee-4cd9-9776-8086645d19e4 | 2024-09-21 | Warnings, Adverse reactions | Rivastigmine |
| Rivastigmine | RIVASTIGMINE | Amneal Pharmaceuticals LLC | 8b671fc9-8cb0-4406-a9ee-7c95086d6200 | 2024-07-02 | Warnings, Adverse reactions | Rivastigmine |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | Aurobindo Pharma Limited | c246a0e5-1e77-41ee-a7b3-384f21f2f2e0 | 2024-06-19 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| Rivastigmine | RIVASTIGMINE | Zydus Pharmaceuticals USA Inc. | 64dad603-2389-456b-8c18-d1d40b7e7419 | 2024-05-27 | Warnings, Adverse reactions | Rivastigmine |
| Rivastigmine | RIVASTIGMINE | Sandoz Inc | 92a58ebb-748d-49f4-bf11-ecbcf5424152 | 2024-05-08 | Warnings, Adverse reactions | Rivastigmine |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | Chartwell RX, LLC | 2bb5e0d6-f677-4021-9888-3ff90979ef7d | 2023-10-06 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | Alembic Pharmaceuticals Limited | 33e6a772-382d-45f5-9d45-966c07759367 | 2023-01-16 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | Cadila Pharmaceuticals Limited | e7e641fe-39bd-4681-a430-6dedeb6d6af5 | 2022-12-29 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | Modavar Pharmaceuticals LLC | 209f3b02-0acf-46e9-b355-91c918a20eb3 | 2022-12-28 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| RIVASTIGMINE TARTRATE | RIVASTIGMINE TARTRATE | Macleods Pharmaceuticals Limited | 4364f6ef-a8da-4805-be0d-aabbe8ca2d21 | 2022-08-24 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | Alembic Pharmaceuticals Inc. | 0044f1d7-613c-4611-8481-13032c8cb390 | 2022-03-21 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| RIVASTIGMINE TARTRATE | RIVASTIGMINE TARTRATE | Nivagen Pharmaceuticals, Inc. | 83bd2ff6-1d8b-4cac-a37b-fd01dc3f34a1 | 2022-02-16 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | Sun Pharmaceutical Industries, Inc. | bac9ca81-db70-41aa-82af-6c5bb8496846 | 2019-01-31 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
| Rivastigmine Tartrate | RIVASTIGMINE TARTRATE | Dr. Reddy's Laboratories Limited | 0e20124c-725a-0145-996c-2ff908703162 | 2019-01-23 | Warnings, Adverse reactions | RIVASTIGMINE TARTRATE |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 31230 | ORIG | 2006-01-18 |